You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康方生物(09926.HK)将在ESMO2020上公布PD-1/CTLA-4双抗治疗复发或标准疗法治疗失败的间皮瘤患者临试结果
格隆汇 08-03 07:48

格隆汇 8 月 3日丨康方生物-B(09926.HK)发布公告,公司将于2020年9月20日在即将举行的2020欧洲肿瘤内科学会(“ESMO2020”)年会上以口头报告形式公布PD-1/CTLA-4双特异性抗体新药AK104治疗复发或标准疗法治疗失败的间皮瘤患者的有效性及安全性资料。

AK104是公司自主研发的新型的、潜在下一代首创PD-1/CTLA-4双特异性肿瘤免疫治疗骨干药物,旨在实现与肿瘤浸润淋巴细胞(“TIL”),而不是正常外周组织淋巴细胞的优先结合。AK104同时靶向两个经过验证的免疫检查点分子:程式性细胞死亡蛋白1(PD-1)及细胞毒性T淋巴细胞相关蛋白4(CTLA-4),因此已显示出PD-1及CTLA-4单克隆抗体联合疗法的临床疗效以及PD-1和CTLA-4单克隆抗体联合疗法无法提供的良好安全性。AK104专案是2017年国家卫健委及科技部十三五“重大新药创制”科技重大专项支持专案,2017年广东省“珠江人才计划”引进创新创业团队支持专案。被中国医药生物技术协会和《中国医药生物技术》杂志共同评为“2017年中国医药生物技术十大进展”之一。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account